Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK-5536522
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**GSK-5536522** is an investigational mRNA vaccine developed by GSK for the prevention of disease caused by influenza A virus H5N1 subtype, a highly pathogenic avian influenza strain. It functions as an **immunostimulant**, leveraging mRNA technology to elicit immune responses including neutralizing antibodies against H5N1. Originating from GSK, it has advanced to Phase II development as a pre-pandemic preparedness candidate, with earlier Phase I/II studies evaluating safety, reactogenicity, immunogenicity, and dose selection in healthy adults aged 18-85 years.[1][5][6]
- Other names
- F-GlaxoSmithKline-influenza (H5)Flu Pandemic mRNA vaccinemRNA-based investigational pandemic H5 influenza vaccine
02
Targets
H5 HA (Influenza A hemagglutinin H5)
Beyond the preview
Go deeper on GSK-5536522.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK-5536522.